Wilhelm Róbert Wessman (born 4 October 1969) is an Icelandic businessman, and the founder and leader of several pharmaceutical and biotechnology companies including Actavis, Alvogen, Adalvo, Lotus and Alvotech.See company and Wessman's personal websites: https://www.alvogen.com/company/meet-the-chairman, https://www.lotuspharm.com/robert-wessman, https://www.robertwessman.com/operation
Early life Wessman was born in Reykjavík on 4 October 1969 to Wilhelm Wessman, a business person, and Ólöf Svafarsdóttir Wessman, a beautician. He grew up in Seltjarnarnes and moved to Mosfellsbær when he was six years old. He graduated from Menntaskólinn við Sund high school and received a bachelor's degree in business administration from the University of Iceland in 1993. After graduating, he worked for Icelandic shipping firm Samskip for seven years, first in the finance department, then as CEO of its operations in Germany. During that time he also taught mathematics on a part-time basis at the University of Iceland. Wessman has spoken at length about his struggles with dislexia in school but also credits those challenges with giving him determination and the ability to focus on big-picture goals in his later professional life.See for example podcast interviews (in Icelandic): "Chess after dark: Episode 210," Apple Podcasts, 13 December 2024; "#91 Róbert Wessman með Sölva Tryggva," YouTube, 2022.
Career Since 1999, Wessman's career has been focused on the generics and biosimilars sectors of the pharmaceuticals industry. The two domains differ significantly in terms of what they make and sell, but the business challenge common to both is to make and distribute lower-cost versions of brand-name therapeutics whose patent protection has expired.Riley, Sean, "Generics vs. Biosimilars: Similar but Different Advantages". Drug Discovery and Development. 2017-05-15. Retrieved 2022-01-14
Delta, Pharmaco and Actavis In 1999, Wessman was appointed CEO of Delta, a generic drug manufacturer in Reykjavik. Following a merger with another Icelandic pharmaceutical company, Pharmaco, in 2002, Delta was rebranded as Actavis in 2004. Wessman's tenure at Activis was characterized by rapid growth and expansion into international markets through a series of acquisitions across Europe, Asia, and the US. By 2004, the company had acquired 16 companies and had operations in 25 countries, manufacturing and selling hundreds of products.Actavis annual report, 2004 In 2005, Actavis, traded on the Icelandic stock exchange, had a market capitalization of $1.9bn.Landsbankinn analyst research note, 12 April 2005 In 2006, it acquired two US generics companies to enter the US market,"Alpharma Sells Generics Business to Iceland's Actavis," Chemical and Engineering News, 25 October 2005 subsequently acquiring additional manufacturing plants in the US, Russia, Romania and India.Actavis, Annual report 2006 In 2008, Wessman stepped down from his position as CEO of Actavis, by which time it had grown to 11,000 employees and was one of the biggest generic drug companies in the world."Changes at the Helm of Actavis," Biospace, 5 August 2008 Wessman's business strategy at Actavis was documented in a 2008 case study published by Harvard Business School entitled ‘Robert Wessman and Actavis’ “Winning Formula.”’
Alvogen In 2009 Wessman founded the biotechnology company Alvogen.Quentin Webb, "Pharma's "Viking boss" makes generic-drug comeback," Reuters, 29 July 2009 Alvogen started by acquiring a distressed generics maker in New York, and R&D capabilities and product portfolios in New Jersey.Biospace, "Mayer Labs Acquires Today(R) Sponge Distribution Rights," 7 April 2009 Over the following five years, built on a string of acquisitions, Wessman expanded production, the product portfolio and marketing efforts focusing on Eastern Europe and South Asia, then acquiring major production sites in Taiwan and South Korea.Timeline of acquisitions and market expansion By 2017, Alvogen was estimated to be worth $4bn.Carly Helfand, "CVC talks $4B Alvogen sale with Shanghai after just 2 years of ownership," Fierce Pharma, 26 September 2016 Wessman's strategy in building Alvogen has been the subject of two Harvard Business School case studies.Daniel Isenberg and William Kerr, "Alvogen," Harvard Business School, February 2017Daniel Isenberg, William Kerr and Alexis Brownell, "Alvogen: Scaling Entrepreneurship," Harvard Business School, 4 August 2018 Since 2021, Alvogen's former subsidiaries Lotus, based in Taiwan, and Malta-based B2B licensing arm Adalvo have been spun off as companies in their own right, with Wessman as chairman and his holding company Aztiq as major shareholder."Aztiq and Innobic acquire Alvogen’s shares in Lotus and Adalvo in $475m deal," Pharma Business International, 1 December 2021 In July 2025, EQT, a private equity fund linked to the Wallenberg family, acquired a majority stake in Adalvo for an undisclosed sum.Press release, "EQT to acquire Adalvo, a leading B2B dossier developer," 18 July 2025. In summer 2025, Wessman was named Taiwan's top pharmaceutical entrepreneur by CommonWealth Magazine for his leadership of Lotus.LinkedIn post, "Robert selected as top pharmaceutical entrepreneur and Lotus as top pharmaceutical company in Taiwan," July/August 2025.
Alvotech In 2013, Wessman founded Alvotech, a company that manufactures biosimilars. It was founded with a $250m investment from Alvogen to build its headquarters and manufacturing facility on the University of Iceland's campus in central Reykjavik."Alvotech invests US$250m in biopharmaceuticals," Manufacturing Chemist, 6 December 2013 Alvotech's strategy to compete in this market has been to focus solely on biosimilars development and production, with vertically integrated capabilities, enabling tight control over quality and costs, and with commercial partnerships to market its products around the world.See for example the Company Overview in Alvotech's "Form F-4 registration statement" with the SEC, 20 December 2021. Wessman has said that Iceland was not an obvious place to build up a biosimilars company but that he was committed to doing so in his native country."Styrkja nám í líftækni," Viðskiptablaðið, 14 December 2024 By 2024, Alvotech had attracted people from some 70 countries to work for it, principally at the headquarters in Reykjavik.Alvotech's Equality Report 2024, posted on company website. He estimated that over $1 billion had been invested in Alvotech before it began to bring in product revenue.Róbert Wessman, "A Landmark Year for Alvotech," LinkedIn post, 5 April 2024
In June, 2022, Alvotech was listed on the Nasdaq stock market"Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16," Nasdaq.com, 15 June 2022 in New York and Iceland through a merger with Special-purpose acquisition company (or SPAC) Oaktree Acquisition Corp. II, trading under the ticker symbol ALVO. In 2025, following the acquisition of the R&D operations and a lead biosimilar candidate of Stockholm-based Xbrane,"Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®," Financial Times, 4 June 2025 the company carried out equity placements in SwedenMalin Otmani, "Alvotech completes SEK 750 million private placement," Nordic Life Science, 5 June 2025 and listed on Nasdaq Stockholm as well.Press release, "Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today," Nasdaq Stockholm, 19 May 2025
In 2024, the company's manufacturing facility in Reykjavik was certified by the US Food and Drug Administration (FDA) and the company was able to begin selling its first product on the US market: Simlandi, a biosimilar to the high-dose version of autoimmune therapy Humira."Humira Biosimilar Simlandi Now Available in the US," Practical Dermatology, 21 May 2024. In early 2025, the company launched a second product, Selarsdi, a biosimilar to Stelara, on the US and European markets.Press release, "Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.," 21 February 2025. It was marketing both in several regions around the world and in August 2025, a third product, a biosimilar to the retinal disease drug Eylea, was approved in Europe.Press release, "Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®," 28 August 2025. The company expected several additional products to be approved in the US, Europe and other markets in the remainder of 2025.Company financial results presentation, "Q2 2025 Earnings and Business Update," 14 August 2025. Alvotech had revenue of $492m in 2024, its first year with significant product sales, and guided for revenue of $600-700m for 2025.Company financial results, "Q1 2025 Earnings Call," 8 May 2025. The company continued its strategy of vertical integration by acquiring its former packaging supplier, Swiss-based Ivers-Lee, in July 2025.Dean Rudge, "Alvotech Boosts Packaging Abilities With Ivers-Lee Acquisition," Generics Bulletin, 10 July 2025.
Personal life Wessman and his wife have six children between them. He is an avid and formerly competitive cyclist, and owns a vineyard at Saint Cernin in southwestern France.Podcast (in Icelandic), "#91 Róbert Wessman með Sölva Tryggva," YouTube, 2022. Maison Wessman has launched a wine label with musician Nora JonesOscar Hartzog, "Inside Norah Jones’ New Life: A Wine Brand, Rowdy Crowds, & Billie Eilish Concerts," Rolling Stone, 20 June 2025 and a collection with Icelandic rock band Kaleo's lead singer Jökull Júlíusson."Le leader de KALEO, JJ Julius Son, et l’entrepreneur Robert Wessman lancent une collection unique de vins en édition limitée à WineParis," Les Echos, 6 February 2025
References